Zura Bio Q4 2024 Earnings Report
Key Takeaways
Zura Bio reported cash and cash equivalents of $188.2 million as of September 30, 2024. Research and development expenses were $6.0 million, and general and administrative expenses were $13.3 million for the third quarter of 2024. Net loss for the third quarter of 2024 was $22.9 million or $0.26 per share.
Made significant progress toward initiating the first Phase 2 trial of tibulizumab in SSc.
Working closely with a contract research organization (CRO) to begin trial readiness and prepare for site activation.
Selected a CRO to support the anticipated Phase 2 trial initiation for tibulizumab in HS in the second quarter of 2025.
Existing cash and cash equivalents and investments should be sufficient to support operations as currently planned through 2027.